Hand-rehab robots placed in small-city physio clinics, paid per session
TL;DR Palmtrain puts licensed, Indian-made hand-rehabilitation robots into physiotherapy clinics in smaller cities at no upfront cost, then shares the fee for each robot-assisted session. Clinics get equipment they could never justify buying, patients get more repetitions per visit and Palmtrain earns from use rather than sales.
India sees about 5.4 lakh new ischaemic strokes a year, and around 65 lakh people live with the after-effects[1]. Many can't use one hand well enough to button a shirt or hold a cup. Recovery depends on hundreds of repeated movements, but a physiotherapist in a small city sees a patient for 30–45 minutes and can only guide so many.
Rehab robots that repeat movements and track progress mostly sit in big-city hospitals. A clinic in a tier-2 town with three therapists isn't going to spend lakhs on a device it might use twice a day. So patients either travel or settle for less therapy than the evidence suggests they need.
What it does, in regulatory terms: a therapy device used under a physiotherapist's supervision, which counts as treatment. Palmtrain buys only robots that hold a licence under India's Medical Devices Rules 2017[2], and the clinic's physiotherapist prescribes and runs each session. Palmtrain makes no recovery claims of its own.
The model is placement, not manufacture. Palmtrain buys hand and wrist robots from Indian makers like the startup that commercialises the PLUTO device from IIT Madras and CMC Vellore[3]. It installs one in a partner clinic, trains the staff and runs a simple app that books sessions, logs repetitions and range of motion, and prints a progress sheet for the patient's neurologist.
The seed proposed building AI-driven robotic therapy, and we reframed it. Building and licensing a new robot takes years, while Indian devices already exist and sit idle for lack of distribution. Cochrane reviewers found robot-assisted arm training gives small but real gains in daily activities and arm function[4], so Palmtrain sells extra practice - not a cure.
The patient or family pays the clinic per session, just as they already do for physiotherapy. The clinic keeps an agreed share and Palmtrain takes the rest. I couldn't find a public price for robot-assisted sessions in India, so test the fee against what a clinic charges for a normal session in its town. Insurers and hospital day-care units can come later.
Indian hand robots reached clinics in the last two years, and PLUTO was licensed for commercial use and has served over 1,000 patients[3]. A 2018 Cochrane update gave the first high-certainty evidence for arm robots[4]. Stroke numbers keep rising with an ageing population[1].
We found no public figure for robotic rehab spending in India. The firmer number is need - about 65 lakh people living after ischaemic stroke[1], plus spinal cord injury and hand-surgery patients. Next door, 2.2% of Indians report a disability, and one in five gets no government aid[5]. Treat that as context for unmet demand, not as a market.
That startup sells PLUTO to hospitals and clinics directly[3]. A Kerala robotics firm places gait robots in Kerala hospitals, which shows Indian rehab robots can reach public settings. Large hospital chains buy imported arm robots for their own units. The gap is a pay-per-use route into the thousands of small private physio clinics that will never buy outright.
| Difficulty | Moderate (45/100) |
| Starting capital | ₹0.8–1.5 Cr |
| Time to launch | 6–9 months |
The devices exist, so the hard parts are commercial. You need makers willing to sell at volume pricing, clinics that will actually book sessions and a way to see usage so the revenue share stays honest. Servicing robots spread across many towns isn't cheap either.
Yes, this is regulated. The robots are medical devices and the sessions are treatment, though Palmtrain itself doesn't manufacture.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Palmtrain supports treatment that a physiotherapist prescribes and runs. AI should not change therapy settings on its own or predict a patient's recovery, and the evidence for robot training shows small gains, not cures.
Want to work out the AI layer for Palmtrain? Talk to Yash →
I think this suits a founder from physiotherapy or medical-equipment sales who knows small-city clinics well. It's not for anyone who wants to invent hardware. First prove one number - a placed robot doing at least 40 paid sessions a month within three months in a tier-2 clinic.
Expect about ₹0.8–1.5 Cr, mostly licensed Indian hand robots placed in clinics, plus training and service.
You need devices licensed with CDSCO, qualified physiotherapists running sessions and registered partner clinics where the state requires it.
Yes, small clinics everywhere can't buy these robots outright. Check that each device is cleared by your own medical device regulator.
The free Palmtrain validation kit has the line-by-line capital breakdown, the effort scoring, the device and clinic rules checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for clinics and patients, and 5 assumptions to test. Download the kit →
Thinking about building Palmtrain or something close to it? The make-or-break work is keeping each placed robot busy enough to pay for itself, and that's a numbers game I'm happy to work through with you. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.